Brief: FDA Approves First-Of-Its-Kind Device To Treat Pancreatic Cancer
12/02/2026 14:05
Feb 12 (Reuters) - Novocure Ltd NVCR.O: FDA APPROVES FIRST-OF-ITS-KIND DEVICE TO TREAT PANCREATIC CANCER FDA: APPROVED NOVOCURE'S OPTUNE PAX, A FIRST-OF-ITS-KIND DEVICE FOR TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED PANCREATIC CANCER Source text: [ID:] Further company coverage: NVCR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovoCure
See all newsOncology firm Novocure says cyberattack exposed US patient records
Novocure Ltd reports results for the quarter ended June 30 - Earnings Summary
Novocure Q2 revenue beats, lifts 2026 outlook
Brief: Novocure Q2 Revenue USD 183.584 Million Vs. IBES Estimate USD 172.4 Million
U.S. STOCKS ON THE MOVE-Kardigan, Energy companies, Take-Two, Accenture